The “failure” of other drugs is a bit of a headline itsgas likes pumping - sure Pfizer GT failed but they were always a back runner & Sarepta missed hitting the primary endpoint but they showed improvements on many other measures - even on the small pt range they have they’re pulling in significant revenue.
Dangerous time to be writing Sarepta off though given FDA outcomes a week today & i think highly likely they will get the expanded label given the improvements shown outside of the primary endpoint.
PER Price at posting:
9.2¢ Sentiment: None Disclosure: Held
